Baclofen-associated encephalopathy in a hemodialysis patient with hiccups

Servicio de Nefrología y Trasplante Renal, Hospital Clinic, Barcelona.
Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia (Impact Factor: 1.22). 02/2006; 26(4):486-8.
Source: PubMed


Baclofen is a centrally acting gamma-ammino butyric acid agonist that is used like muscular relaxant in disorders with spasticity and intractable hiccups. Although encouraging and safe results were provided 5 mg/day in hemodialysis patients, his pharmacokinetic and pharmacodinamic properties are not well known in end stage renal disease. We present here the case of a hemodialysis patient with intractable hiccups who developed baclofen-associated encephalopathy with this recommended dose.

Download full-text


Available from: Luis F Quintana,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Intractable singultus is a rare but significantly disruptive clinical phenomenon that often accompanies other diseases but can present in isolation due entirely to intracranial pathology. We report a case of intractable singultus that improved after microvascular decompression and present a comprehensive review of singultus by discussing its similarity to other cases of microvascular decompression, its history and etiology, and its evolutionary basis. The patient exhibited intractable singultus for 15 years, resistant to multiple medical regimens. Microvascular decompression to relieve pressure on the tenth cranial nerve and medulla oblongata resulted in near total resolution of the singultus. Neurovascular compression should be considered a potentially reversible cause of intractable singultus, a significantly disabling clinical phenomenon.
    Neurosurgery 06/2008; 62(5):E1180-1; discussion E1181. DOI:10.1227/01.neu.0000325888.84785.20 · 3.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This chapter elaborates studies focusing on neuromuscular blocking agents and skeletal muscle relaxant. The mechanism of a delayed hypersensitivity reaction to suxamethonium has been studied by harvesting the patient's T cells from a biopsy at the site of positive intradermal reactions and analyzing the immunophenotype, T cell receptor Vβ domain expression, and cytokine profile. The T cells proliferated dose-dependently in response to drug-pulsed autologous antigen-presenting cells. The drug-specific CD4+ T cells were oligoclonal memory CD3+CD4+ T cells and expressed the skin-homing receptors cutaneous lymphocyte antigen (CLA) and CCR4. The adverse effects of botulinum toxin type A were reviewed and subjected to systematic review in an analysis of data from nine double-blind, placebo-controlled studies in 792 patients with spasticity after stroke. Most of the patients (69%) received only one injection. After follow-up for a mean of 18 of the patients who had been given toxin type A group and 163 (63%) of those who had been given placebo reported at least one adverse event. The most frequent adverse events were respiratory infections, seizures, incoordination, and injection site pain, none of which occurred at a significantly higher rate with the toxin. Most of the adverse events were rated as mild or moderate in intensity.
    Side Effects of Drugs Annual 12/2009; 31:247-257. DOI:10.1016/S0378-6080(09)03112-2

  • Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia 09/2011; 31(5):611-2. DOI:10.3265/Nefrologia.pre2011.Jun.10921 · 1.22 Impact Factor